Key result
RotaTeq reduces rotavirus gastroenteritis hospitalizations by ~100%.
Why the study?
Does the oral pentavalent rotavirus vaccine reduce hospitalizations and healthcare utilization for rotavirus gastroenteritis in industrialized countries?
Systematic Review
Yes
Does the oral pentavalent rotavirus vaccine reduce hospitalizations and healthcare utilization for rotavirus gastroenteritis in industrialized countries?
Effect estimate: Effectiveness up to 100% (95% CI 85-100)
The oral pentavalent rotavirus vaccine is highly effective in routine use, significantly reducing hospitalizations and emergency department visits for rotavirus gastroenteritis in industrialized countries.
Supports routine RotaTeq use in industrialized countries; confirms high real-world effectiveness against rotavirus hospitalizations.
The pentavalent rotavirus (RV) vaccine RotaTeq™ has been available in industrialized countries since 2006. Several studies have been conducted to evaluate the benefit of RV vaccination under routine conditions of use. A systematic review of all publicly available data from RotaTeq™ vaccine-effectiveness and vaccination-impact studies in the USA, Europe and Australia between 2006 and February 2010 was undertaken. Depending on the population studied, effectiveness of up to 100% (95% confidence interval 85-100%) associated with decreased hospitalizations for RV gastroenteritis (RVGE) was seen. Vaccination-impact studies demonstrated that the burden of RVGE has been reduced significantly since the introduction of RV vaccination. Evidence included reductions in healthcare utilization due to RVGE (hospitalizations and emergency-department visits reduced by up to 90%), reductions in the magnitude and duration of the RV season as assessed by laboratory testing for RV, and the possible induction of herd immunity.
No takes yet. Share an insight, caveat, or question.
Giaquinto et al. (2011) conducted a systematic review in Rotavirus gastroenteritis. Oral pentavalent rotavirus vaccine (RotaTeq™) was evaluated on Hospitalizations for rotavirus gastroenteritis (RVGE) (Effectiveness up to 100%, 95% CI 85-100). The oral pentavalent rotavirus vaccine RotaTeq™ demonstrated effectiveness of up to 100% (95% CI 85-100%) in decreasing hospitalizations for rotavirus gastroenteritis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: